Veterinary Vaccines Market

The veterinary vaccines market is projected to reach USD 18.46 billion by 2031 from an estimated USD 13.02 billion in 2026, at a CAGR of 7.2%.

The veterinary vaccines market is experiencing significant growth, primarily driven by the expanding companion animal population, rising pet ownership, the increasing incidence of zoonotic diseases, and government initiatives to improve animal health. On the other hand, the high cost of vaccines is expected to restrain this market's growth to some extent. Navigating these drivers and restraints will be crucial for the future development and adoption of veterinary vaccine solutions.

To know about the assumptions considered for the study download the pdf brochure

Some of the prominent players operating in the market include Zoetis (US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu Biotechnology Co., Ltd. (China), China Animal Husbandry Industry Co., Ltd. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V. (Netherlands).

Zoetis (US)

Zoetis develops and manufactures animal health medicines and vaccines, as well as diagnostic products, genetic tests, biodevices, and a range of services designed to meet the needs of veterinarians, livestock farmers, and companion animal owners. Zoetis discovers, develops, manufactures, and commercializes a wide portfolio of vaccines and medicines for livestock and companion animals. The company's major product categories include anti-infectives, vaccines, parasiticides, dermatology, medicated feed additives, other pharmaceuticals, animal health diagnostics, other non-pharmaceuticals, and contract manufacturing & human health. Zoetis operates in North America, Europe, the Middle East & Africa, Latin America, and the Asia Pacific. The company has robust R&D operations focused on vaccines, devices, data, digital, and other technological innovations.

Merck & Co., Inc. (US)

Merck & Co., Inc. is a global healthcare company that delivers innovative solutions for animal healthcare. The company operates through two segments: Pharmaceutical and Animal Health. The Animal Health segment discovers, develops, manufactures, and markets a wide range of veterinary pharmaceutical & vaccine products for various animal species. The company operates in over 50 countries across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck focuses on inorganic growth strategies, such as acquisitions, agreements, and expansions, to grow in the veterinary vaccines market.

Boehringer Ingelheim International GmbH (Germany)

Boehringer Ingelheim International GmbH is engaged in the research, development, production, and sales of various pharmaceutical products. The company operates through four basic segments—Human Pharma, Animal Health, Biopharmaceutical Contract Manufacturing, and Discontinued Operations. The company's Animal Health business includes a wide range of biological, pharmaceutical, and natural care products for food-producing and companion animals. The company has 151 subsidiaries worldwide. In 2025, the company achieved the milestone of four billion doses sold. Also, Boehringer's strategic partnerships and global reach enhance its ability to meet evolving market demands, positioning it as a leader in the competitive veterinary vaccines sector.

Related Reports:

Veterinary Vaccines Market by Type (Porcine, Poultry, Bovine, Ruminant, Canine, Feline, Aquaculture), Technology (Live Attenuated, Inactivated, Toxoid, Recombinant), Route of Administration (Subcutaneous, Oral), End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]